USANA Health Sciences (NASDAQ:USNA) Director Myron W. Wentz unloaded 14,000 shares of the stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $73.78, for a total transaction of $1,032,920.00. USANA Health Sciences, Inc. (NYSE:USNA) net profit margin is 10.60% and weekly performance is -0.72%. On last trading day company shares ended up $69.05. Analysts mean target price for the company is $79.00. USANA Health Sciences, Inc. (NYSE:USNA) distance from 50-day simple moving average (SMA50) is -5.90%.
Perrigo Company (NASDAQ:PRGO) Director Ran Gottfried sold 1,000 shares of the company’s stock on the open market in a transaction dated Thursday, May 15th. The shares were sold at an average price of $131.25, for a total transaction of $131,250.00. Following the sale, the director now directly owns 12,159 shares of the company’s stock, valued at approximately $1,595,869. Perrigo Company (NYSE:PRGO) shares advanced 0.32% in last trading session and ended the day on $132.80. PRGO Gross Margin is 52.10% and its return on assets is 11.50%. Perrigo Company (NYSE:PRGO) quarterly performance is -10.98%.
ProPhase Labs, Inc. (NASDAQ:PRPH) on 12 May 2014 reported net sales of $6.2 million for the three months ended March 31, 2014 as compared to net sales of $7.5 million for the three months ended March 31, 2013. The Company incurred a net loss for the three months ended March 31, 2014, of ($804,000), or ($0.05) per share, compared to net income of $290,000, or $0.02 per share, for the three months ended March 31, 2013. The financial results for the three months ended March 31, 2014 as compared to three months ended March 31, 2013 reflect the net effect of (i) a decrease of our revenues due principally to (a) industry data suggesting there was reduction of over 12% in the incidence of upper respiratory disorders from period to period and, as a consequence, (b) the timing of purchases and the ultimate level of demand for our products, (ii) an increase in research and development expenditures of $90,000 as we seek to expand our future product offerings to consumers, offset by (iii) a decrease in sales and marketing expenses of $366,000 as a consequence of the fluctuation from period to period of the timing and scope of our marketing initiatives. ProPhase Labs Inc (NASDAQ:PRPH) shares moved up 0.02% in last trading session and was closed at $1.85, while trading in range of $1.80 – $1.85. ProPhase Labs Inc (NASDAQ:PRPH) year to date (YTD) performance is 14.91%.
Natural Alternatives International, Inc. (NASDAQ:NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, on 13 May 2014 announced net income of $622,000 or $0.09 per diluted share on net sales of $19.1 million for the quarter ended March 31, 2014. Net sales for the three months ended March 31, 2014 increased by $3.3 million or 20.8% from $15.8 million recorded in the comparable prior year period. For the quarter ended March 31, 2014, contract manufacturing sales increased $3.2 million or 22.0% from the comparable quarter last year due primarily to higher sales of established products to existing costumers and new product sales to new customers. Patent and trademark licensing revenue increased 13.1% to $1.1 million during the quarter ended March 31, 2014 as compared to the prior year period. Branded products sales totaled $294,000 for the third quarter of fiscal 2014 as compared to $321,000 for the comparable prior year period. Natural Alternatives International, Inc. (NASDAQ:NAII) ended the last trading day at $5.69. Company weekly volatility is calculated as 3.38% and price to cash ratio as 2.43. Natural Alternatives International, Inc. (NASDAQ:NAII) showed a positive weekly performance of 5.60%.
LifeVantage Corp (NASDAQ:LFVN) on the daily charts has been forming lower highs and lower lows and hasn’t found strong momentum on the buy side. The stock has been falling right from the time it hit the intraday high of $1.51 and has seen the stock fall below an important trend line support. The momentum indicators for LifeVantage Corp (NASDAQ:LFVN) have given a bearish crossover which is a sell signal, and in my opinion traders should go short on the stock with a strict stop loss at $1.51 with a target of $1.24 in the near term. LifeVantage Corp (NASDAQ:LFVN) net profit margin is 4.80% and weekly performance is 2.94%. On last trading day company shares ended up $1.40. Analysts mean target price for the company is $2.10. LifeVantage Corp (NASDAQ:LFVN) distance from 50-day simple moving average (SMA50) is 0.91%.